|Isis Pharmaceuticals, Inc.|
2855 Gazelle Court
United States - Map
Isis Pharmaceuticals, Inc. engages in the discovery and development of antisense drugs using novel drug discovery platform. The companys flagship product, KYNAMRO injection, is an apo-B synthesis inhibitor for patients with homozygous familial hypercholesterolemia for the reduction of low-density lipoprotein cholesterol. It also has a pipeline of 28 drugs in development for the treatment of cardiovascular, severe and rare, neurologic, and metabolic diseases, as well as cancer. The company has collaboration agreements with AstraZeneca to discover and develop antisense drugs against five cancer targets; Biogen Idec to develop and commercialize ISIS-SMNRx for the treatment of spinal muscular atrophy; and Bristol-Myers Squibb to discover, develop, and commercialize antisense drugs targeting proprotein convertase subtilisin/kexin type 9. In addition, it has strategic alliances with Eli Lilly and Company for the development of LY2275796, an antisense inhibitor of eIF-4E; Genzyme Corporation for the licensing and co-development of KYNAMRO; GlaxoSmithKline to develop drugs against targets for rare and serious diseases, including infectious diseases and conditions causing blindness; and Biogen Idec to discover and develop antisense drugs to treat neurological disorders. Isis Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Carlsbad, California.
|Isis Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Mar 1, 2014 is 6. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 5; Compensation: 5.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Stanley T. Crooke M.D., Ph.D.,
Founder, Exec. Chairman, Chief Exec. Officer, Pres and Member of Non-Management Stock Option Committee
|Ms. B. Lynne Parshall Esq., J.D.,
Chief Operating Officer, Corp. Sec. and Director
|Dr. C. Frank Bennett BSc, Ph.D.,
Sr. VP of Antisense Research
|Dr. Richard S. Geary Ph.D.,
Sr. VP of Devel.
|Mr. Brett P. Monia Ph.D.,
Sr. VP of Drug Discovery & Corp. Devel.
|Amounts are as of Dec 31, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|